The deal provides a clear path to monetizing VIZZ in China, with near-term milestone payments and long-term royalty stream. Monitor for regulatory approval in Q1 2027 and potential additional partnership announcements for other regions. The stock may re-rate on reduced China regulatory risk and expanded commercial reach.
Price Chart
Executive Summary
LENZ Therapeutics announced that Everest Medicines has acquired the rights to develop and commercialize VIZZ (LNZ100) in Greater China from Corxel Pharmaceuticals. LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones plus tiered royalties on net sales, and additional payments from the agreement execution. The deal advances LENZ's international licensing strategy for its presbyopia treatment, which is already FDA-approved in the U.S. and under NDA review in China with approval anticipated in Q1 2027.
Key Financial Metrics
Key Facts
- Everest Medicines acquired rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China from Corxel Pharmaceuticals.
- LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones plus tiered mid single-digit to low double-digit royalties on net sales in Greater China.
- LENZ is also eligible for additional payments in connection with the execution of the agreement between CORXEL and Everest.
- The NDA for LNZ100 in China was submitted in September 2025, with approval anticipated in Q1 2027.
- VIZZ is the first and only FDA-approved aceclidine-based eye drop for presbyopia, impacting an estimated 1.8 billion people globally.
Financial Impact
Up to $85.0 million in milestones plus tiered royalties and additional upfront payments; deal value not fully disclosed.
Risk Factors
- Regulatory approval in China is not guaranteed and could be delayed or denied.
- Commercial success in Greater China depends on market adoption, pricing, and competition.
- Milestone payments are contingent on achieving specific regulatory and sales events.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307756 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $3.25 | awaiting T+1 | — | $3.15 (−3.08%) |
Oct 21, 2026 5d ago | SC 13G/A | $3.25 $3.16 | ▼ −2.77% | ▼ −2.25% | $3.15 (−3.08%) |
Aug 11, 2026 10w ago | Press Release | $5.04 $4.60 | ▼ −8.73% | ▼ −9.43% | $3.15 (−37.50%) |
Jul 2, 2026 16w ago | 8-K | $5.89 $5.60 | ▼ −4.92% | ▼ −5.80% | $3.15 (−46.52%) |
Jun 11, 2026 19w ago | Institutional Cluster | $6.50 $6.77 | ▲ +4.15% | ▲ +3.61% | $3.15 (−51.54%) |
Jun 7, 2026 20w ago | Press Release | $6.72 $6.79 | ▲ +1.04% | ▲ +1.34% | $3.15 (−53.12%) |
May 11, 2026 24w ago | 8-K | $7.91 $7.91 | · 0.00% | ▼ −0.54% | $3.15 (−60.18%) |
May 4, 2026 25w ago | Press Release | $9.28 $9.07 | ▼ −2.26% | ▼ −3.06% | $3.15 (−66.06%) |
Mar 24, 2026 31w ago | Press Release | $9.03 $9.07 | ▲ +0.44% | ▼ −0.12% | $3.15 (−65.12%) |
Feb 28, 2026 34w ago | Institutional Cluster | $13.68 $13.15 | ▼ −3.87% | ▼ −2.96% | $3.15 (−76.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers